Abstract
A total of 10 breast cancer and 7 control cell lines have been used as target cells in ADCC tests to detect antibodies to surface antigens of these cell lines using sera from 125 breast cancer patients and 109 controls. Five of the breast cancer cell lines elicited some breast cancer associated activity. Significantly more breast cancer patient sera reacted with PMC9, 47% ( P < 0.001) and MDA-MB157, 48% ( P < 0.025) than other cancer patient or normal sera. Breast cancer patient reactivity to PMC42, 41% and MDA-MB231, 37%, was significantly ( P < 0.05) greater than that of normal sera, and greater, but not significantly different, than that of other cancer patients. Five other breast cancer cell lines HS578T, MDA-MB415, BT20, T47D, and MCF-7 elicited reactivity which was similar for all serum groups. Reactivity of breast cancer sera to control cell lines was significantly ( P < 0.05) lower than to PMC9. Patterns of breast cancer reactivity against a panel of breast cancer cell lines varied, suggesting incomplete cross-reactivity between surface antigens of breast cancer cell lines. Absorption studies of breast cancer sera with a breast cancer cell line indicated that there are a number of surface antigens present on these cell lines which are recognised by breast cancer sera.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
